Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K7OW
|
||||
| Former ID |
DIB016664
|
||||
| Drug Name |
GSK-1360707
|
||||
| Synonyms |
Monoamine reuptake inhibitors (depression), GlaxoSmithKline; Serotonin/dopamine/norepinephrine reuptake inhibitors (depression), GlaxoSmithKline
|
||||
| Indication | Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32] | Phase 1 | [523095] | ||
| Company |
GlaxoSmithKline plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1NCC[C@]2([C@@]1(C2)COC)c1ccc(c(c1)Cl)Cl
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Inhibitor | [532361] | |
| Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [532361] | ||
| Sodium-dependent dopamine transporter | Target Info | Inhibitor | [532361] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis | |||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter ActivityWP727:Monoamine Transport | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic Cleft | |||||
| References | |||||
| Ref 523095 | ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.